ERAS
Price
$1.57
Change
-$0.00 (-0.00%)
Updated
Aug 29 closing price
Capitalization
445.36M
66 days until earnings call
LRMR
Price
$3.62
Change
-$0.29 (-7.42%)
Updated
Aug 29 closing price
Capitalization
309.84M
80 days until earnings call
Interact to see
Advertisement

ERAS vs LRMR

Header iconERAS vs LRMR Comparison
Open Charts ERAS vs LRMRBanner chart's image
Erasca
Price$1.57
Change-$0.00 (-0.00%)
Volume$511.23K
Capitalization445.36M
Larimar Therapeutics
Price$3.62
Change-$0.29 (-7.42%)
Volume$1.4M
Capitalization309.84M
ERAS vs LRMR Comparison Chart in %
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. LRMR commentary
Aug 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and LRMR is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 31, 2025
Stock price -- (ERAS: $1.57 vs. LRMR: $3.62)
Brand notoriety: ERAS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 67% vs. LRMR: 103%
Market capitalization -- ERAS: $445.36M vs. LRMR: $309.84M
ERAS [@Biotechnology] is valued at $445.36M. LRMR’s [@Biotechnology] market capitalization is $309.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while LRMR’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 4 bearish.
  • LRMR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than LRMR.

Price Growth

ERAS (@Biotechnology) experienced а -1.87% price change this week, while LRMR (@Biotechnology) price change was -7.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.70%. For the same industry, the average monthly price growth was +20.57%, and the average quarterly price growth was +29.45%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

LRMR is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (-0.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($445M) has a higher market cap than LRMR($310M). LRMR YTD gains are higher at: -6.460 vs. ERAS (-37.450). LRMR has higher annual earnings (EBITDA): -108.21M vs. ERAS (-135.93M). ERAS has more cash in the bank: 301M vs. LRMR (139M). LRMR has less debt than ERAS: LRMR (4.61M) vs ERAS (49.4M). ERAS (0) and LRMR (0) have equivalent revenues.
ERASLRMRERAS / LRMR
Capitalization445M310M144%
EBITDA-135.93M-108.21M126%
Gain YTD-37.450-6.460580%
P/E RatioN/AN/A-
Revenue00-
Total Cash301M139M217%
Total Debt49.4M4.61M1,071%
FUNDAMENTALS RATINGS
LRMR: Fundamental Ratings
LRMR
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ERASLRMR
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PKAPX14.42-0.01
-0.07%
PIMCO RAE US I-2
CCMAX9.74-0.02
-0.20%
Conestoga Mid Cap Institutional
HFAHX16.21-0.07
-0.43%
Hartford Schroders Intl Cntrrn Val Y
FEYIX29.76-0.19
-0.63%
Fidelity Advisor Asset Manager 85% I
TVRRX84.42-0.77
-0.90%
Thornburg Small/Mid Cap Core R5

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with EYPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-7.42%
EYPT - LRMR
48%
Loosely correlated
-0.26%
SYRE - LRMR
48%
Loosely correlated
-1.38%
OCUL - LRMR
48%
Loosely correlated
-2.48%
ERAS - LRMR
47%
Loosely correlated
N/A
ACLX - LRMR
47%
Loosely correlated
-1.22%
More